Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
fosaprepitant dimeglumine, Quantity: 245.3 mg (Equivalent: fosaprepitant, Qty 150 mg)
Reach Pharmaceuticals Pty Ltd
Injection, powder for
Excipient Ingredients: lactose; polysorbate 80; hydrochloric acid; sodium hydroxide; disodium edetate
Intravenous Infusion
1 vial
(S4) Prescription Only Medicine
FOSAPREPITANT MSN, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration),? moderately emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration).
Visual Identification: White to off-white sterile lyophilised cake or powder in a 10 mL type-I clear vial with bromobutyl rubber stopper and sealed with aluminium flip off seal.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2022-10-19
FOSAPREPITANT® 1 FOSAPREPITANT MSN The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FOSAPREPITANT MSN contains the active ingredient fosaprepitant (as dimeglumine). FOSAPREPITANT MSN is used for chemotherapy induced nausea and vomiting. For more i nformation, see Section 1. Why am I using FOSAPREPITANT MSN? in the full CMI. Do not use if you have ever had an allergic reaction to fosaprepitant or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I am given FOSAPREPITANT MSN? in th e full CMI. Some medicines may interfere with FOSAPREPITANT MSN and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in th e full CMI. • FOSAPREPITANT MSN is to be given intravenously by your doctor and it contains 150 mg of fosaprepitant as the active ingredient. • FOSAPREPITANT MSN must only be administered by your doctor or nurse. More instructions can be found in Section 4. How is FOSAPREPITANT MSN given? in th e full CMI. THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using FOSAPREPITANT MSN. • Women taking oral contraceptive pills for birth control should also use other methods of contraception during treatment with FOSAPREPITANT MSN and for one month following the last dose of FOSAPREPITANT MSN. DRIVING OR USING MACHINES • Be careful driving or operating machinery until you know how FOSAPREPITANT MSN affects you. • FOSAPREPITANT MSN generally does not cause any problems with your ability to drive a car or operate machinery. STORAGE • FOSAPREPITANT MSN will be stored in the pharmacy or on the ward in the hospital. • It is kept in a refrigerator where the temperature stays between 2-8°C. For more information, see Section 5. What s Read the complete document